LLY

1,041.1

+2.25%↑

JNJ

247.68

+1.83%↑

ABBV

230.26

+2.11%↑

NVS

169.04

+1.88%↑

MRK

123.57

+3.19%↑

LLY

1,041.1

+2.25%↑

JNJ

247.68

+1.83%↑

ABBV

230.26

+2.11%↑

NVS

169.04

+1.88%↑

MRK

123.57

+3.19%↑

LLY

1,041.1

+2.25%↑

JNJ

247.68

+1.83%↑

ABBV

230.26

+2.11%↑

NVS

169.04

+1.88%↑

MRK

123.57

+3.19%↑

LLY

1,041.1

+2.25%↑

JNJ

247.68

+1.83%↑

ABBV

230.26

+2.11%↑

NVS

169.04

+1.88%↑

MRK

123.57

+3.19%↑

LLY

1,041.1

+2.25%↑

JNJ

247.68

+1.83%↑

ABBV

230.26

+2.11%↑

NVS

169.04

+1.88%↑

MRK

123.57

+3.19%↑

Search

Harmony Biosciences Holdings Inc

Aperta

SettoreSettore sanitario

28.47 -1.62

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.94

Massimo

28.6

Metriche Chiave

By Trading Economics

Entrata

11M

51M

Vendite

39M

239M

P/E

Media del settore

8.476

108.767

EPS

1.08

Margine di Profitto

21.242

Dipendenti

268

EBITDA

14M

73M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+46.33% upside

Dividendi

By Dow Jones

Utili prossimi

5 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-140M

1.5B

Apertura precedente

30.09

Chiusura precedente

28.47

Notizie sul Sentiment di mercato

By Acuity

46%

54%

158 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 feb 2026, 22:04 UTC

Utili

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 feb 2026, 23:55 UTC

Discorsi di Mercato

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 feb 2026, 23:40 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 feb 2026, 23:37 UTC

Discorsi di Mercato

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 feb 2026, 23:32 UTC

Utili

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 feb 2026, 23:19 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 feb 2026, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 feb 2026, 23:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

26 feb 2026, 23:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 feb 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 feb 2026, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 22:43 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

26 feb 2026, 22:43 UTC

Discorsi di Mercato

RBA Hike In March Is Being Underpriced -- Market Talk

26 feb 2026, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 feb 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 feb 2026, 22:13 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 feb 2026, 21:59 UTC

Utili

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 feb 2026, 21:58 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

26 feb 2026, 21:49 UTC

Utili

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 feb 2026, 21:45 UTC

Utili

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 feb 2026, 21:44 UTC

Utili

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 feb 2026, 21:44 UTC

Utili

Coles Expects Market to Remain Highly Competitive

26 feb 2026, 21:44 UTC

Utili

Coles Says Supermarket Customers Remain Value Oriented

26 feb 2026, 21:43 UTC

Utili

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 feb 2026, 21:43 UTC

Utili

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 feb 2026, 21:42 UTC

Acquisizioni, Fusioni, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 feb 2026, 21:41 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

46.33% in crescita

Previsioni per 12 mesi

Media 41.25 USD  46.33%

Alto 62 USD

Basso 25 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

4

Acquista

3

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Very Strong Bearish Evidence

Sentiment

By Acuity

158 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat